Navigation Links
Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
Date:5/13/2010

--------------------------------------------- $ $ Cash and cash equivalents 26,947 38,100 Accounts receivable and other current assets 10,383 10,913 Restricted cash 833 878 Property, plant and equipment 3,885 4,358 Other long-term assets 29,924 32,013 ------------------------------------------------------------------------- Total assets 71,972 86,262 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Accounts payable and other current liabilities 14,777 19,211 Current portion of long-term payable 59 57 Long-term payable 118 143 Non-financial long-term liabilities* 53,848 57,625 ------------------------------------------------------------------------- Total liabilities 68,802 77,036 Shareholders' equity 3,170 9,226 ------------------------------------------------------------------------- Total liabilities and shareholders' equity 71,972 86,262 ------------------------------------------------------------------------- ------------------------------------------------------------------------- * Comprised mainly of deferred revenues and employee future benefits.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
3. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
5. AEterna Zentaris Announces Appointment of New Board Member
6. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
8. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
9. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
10. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
11. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 EPFL ... announce the appointment of John P. Donoghue . ...   in  Geneva . The new ... Biotech in Geneva , has named ... neuroscientists. John P. Donoghue , founder of Brown ...
(Date:7/10/2014)... July 10, 2014 Women in ... access to an additional family planning option. Sayana® ... contraception at all levels of the health system ... of a widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone ... Faso is the first of four African countries ...
(Date:7/10/2014)... Boston, Mass. (PRWEB) July 10, 2014 ... , today announced that Alan Swahn, a former vice ... Terascala’s executive team as vice president of marketing. Terascala’s ... from Dell and NetApp create the highest performance and ... has been appointed to guide Terascala’s channel expansion and ...
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... , BOTHELL, Wash., Aug. 7 SCOLR Pharma, ... for the three and six months ended June 30, 2009. ... President and CEO, said, "We continue to advance discussions with a ... potential partners have been committing resources to due diligence and preliminary ...
... HUNTSVILLE, Ala., Aug. 7 EGEN, Inc. (EGEN), a biopharmaceutical ... that Jason Fewell, Ph.D., has been promoted from Director of ... , , Dr. Fewell possesses more than ... industry and has served at EGEN since 2003 as Director ...
... BRISBANE, Calif., Aug. 7 InterMune, Inc. (Nasdaq: ... Officer and President of InterMune, will present at the Canaccord Adams ... at 10:30 a.m. EDT. , , To access ... parties may log on to the investor relations page of InterMune,s ...
Cached Biology Technology:SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 8EGEN, Inc. Announces the Promotion of Jason Fewell, Ph.D., to Vice-President of Preclinical Research and Development 2
(Date:7/11/2014)... risk of kidney injury related to the use of ... of HES molecules, according to a report in ... Anesthesia Research Society (IARS). , The "total mass of ... cultured human renal proximal tubule cells (PTCs), concludes the ... University Hospital Wrzburg, Austria. Other factorssuch as differences ...
(Date:7/11/2014)... the hippocampus, the marginal division of the striatum ... is the impact degree of substance P in ... function? Yan Yu and his team, College of ... immunofluorescence staining, that substance P receptor, neurokinin 1 ... marginal division of normal rats. Unilateral or bilateral ...
(Date:7/11/2014)... receptor type 1 can inhibit voltage-gated calcium ... neurotransmitter release. However, some scholars demonstrated that ... Ca2+ influx and increase neurotransmitter release. Dr. ... Affiliated to Tongji Medical College, Huazhong University ... cell voltage-clamp and calcium imaging in cultured ...
Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... Ohio Researchers, health care engineers and medical ... National Conference on Value-driven Engineering to Improve Medical ... Austen BioInnovation Institute in Akron (ABIA) and sponsored ... some of the nation,s leading biomedical device engineering ...
... many aspects of who we are from the colour ... but how are the genes, and consequently the proteins they ... new group of molecules which control some of the fundamental ... developing new therapies for treating neurodegenerative diseases. The research, ...
... in German . Leipzig/Dresden/Freiburg. In recent ... around the world. As a team of researchers from the ... Dresden and the University of Freiburg headed by the UFZ ... global pollination benefit" in the open-access journal PLoS ONE ...
Cached Biology News:Medical device, health professionals attend first national conference on value-driven engineering 2Medical device, health professionals attend first national conference on value-driven engineering 3Doubling the information from the double helix 2Global prices of pollination-dependent products such as coffee could rise in the long term 2Global prices of pollination-dependent products such as coffee could rise in the long term 3
5 minutes from gel band to purified DNA...
BD IMag Anti-Mouse CD90.2 (Thy1.2) Particles-MSC 2 x 109 cells...
... Agarose overlays are commonly ... Many commercial "DNA grade" agaroses ... toxic to insect cells or ... to obtain good overlays. Novagen's ...
AgarPlaque Plus Agarose 50 grams...
Biology Products: